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Acyclovir/Cytomegalovirus Immune Globulin Combination Therapy 
for CMV Prophylaxis in High-Risk Renal Allograft Recipients 
G. Carrieri. M.l. Jordan. R. Shapiro, V.P. Scantlebury, C. Vivas, S. Kusne, M. Magnone, J. McCauley, 
and T.E. Starzl 
CYTOMEGALOVIRUS (CMV) remains a common 
complication after renal transplantation. As previ-
ously reported. CMV has a significant impact not only on 
the clinical outcome after transplantation but also on its 
cost; for patients with CMV. cost is increased 2.9-fold as a 
result of extended hospitalization. I 
The risk of developing CMV disease after renal trans-
plantation is highest in seronegative patients who receive 
grafts from seropositive donors (R-D+). In this population, 
the incidence of CMV -associated morbidity approaches 
60%. 
Numerous strategies have been employed to prevent 
CMV disease after transplantation. including the exclusion 
of antibody-positive donors for antibody-negative recipi-
ents," active immunization .... ;th CMV-attenuated vaccines,J 
passive immunization with CMV immunoglobulin (CMV-
Ig).4 and antiviral chemotherapy including high-dose acy-
clovir (ACV),5 gancyciovir.o and interferon.7 Although each 
agent has achieved some success, none has successfully 
eliminated the virus. 
MATERIALS AND METHODS 
Of 792 pallents receiving renal allograft transplants at the Univer· 
sity of Pittsburgh Medical Center (UPMC) between June I, 1989. 
and May l. 1993. 116 (14.60/,,) R-D+ patients were retrospectively 
evaluated. In this 47-month period. two different protocols for 
prophylaxis against CMV were followed; during the tirst 17 months. 
·n patients received high-dose ACV alone (group I); during the 
following 30 months, 73 pallents received high-dose ACV in 
combination with CMV-Ig (group 2). Aq'ciovir dosage was caleu-
l;lted following the guidelines suggested by Balfour et ai' and 
adjusted if required by the clinical situation. The CMV-Ig combi-
nation was administered according to the dosage and schedule 
suggested by pnydmanK~ 
Clinical characteristics of the patients are summarized in Table 
l. Both groups were comparable for age, sex. graft source (living, 
related/cadaver). number of retransplantations. number of highly 
senSItized recipients. and adult vs pediatric recipients. 
In group I. the initial immunosuppressive protocol included FK 
506 and Prednisone (Pred) in 20 patients. ~Dyclosporine (CyA). Prcd 
and Imuran in 16 patients, and CyA and Pred in 7 patients. 
In group 2. all 73 patients received FK 506 and Pred immuno-
-;uppresslOn: 2S patlents also received Imuran (Table I). 
Mean follow-up was 28 months (range, 20 to 38 months) for 
group I. and 13.8 months (range 2.1 to 31 months) for group 2. The 
following laboratory tests were pertormed bdore transplantatlon. 
daily while the patient was in the hospital. and at least weekly for 
the tirst () months posttransplantation: eBC with differential. 
Table 1. ClInical Characteristics and Immunosuppression 
in the Study Groups 
Regimen 
Acyclovir Alone Acyclovir + Globulin 
Number of Patients 43 73 
Sex 
Male 25 (58%) 53(73%) 
Female 18 (42%) 20(27%) 
Mean age (years) 36 (range 4-62) 38 (range 1-67) 
Donor 
Uving 3(7%) 7 (10%) 
Cadaveric 40(93%) 66 (90%) 
Retransplantation 12 (26%) 16 (22%) 
PRA >40% 7 (16%) 10 (14%) 
Adult/pediatric recipients 4112 68/5 
Mean follow-up (months) 28 (range 20-38) 13.8 (range 2.1-31) 
FK 506, Prednisone 20(47%) 45(62%) 




Cyclosporine, Imuran, 16 (37%) 
Prednisone 
dectrolytes, BUN, creatinine, glucose. liver-function profile. cho-
lesterol. calcium, phosphorus, uric acid. and magnesium. 
Before transplantation, CMV titers were measured in all recip-
ients and kidney donors: herpes simplex and Epstein-Barr virus 
titers were also measured. Specimens of urine. buffy coat. and 
throat swabs were collected at weekly intervals until discharge, at 
regular outpatient appointments. and during any subsequent hos-
pital admission to rule out CMV. Specimens from other sites (ie. 
gastrointestinal biopsies. renal biopsies. bronchoalveolar lavage) 
were also processed when invasive CMV disease was investigated. 
Samples were tested for CMV by conventional cell-culture meth-
ods and by shell vial assay for early CMV antigen detection. In 
addition. quantitation of CMV IgG and IgM was also performed 
with an automated immunofluorescent test. 
Asymptomatic CMV infection (ACI) was defined as antibody 
seroconversion not attributable to globulin infusion. and/or viral 
shedding, andlor positive early antigen detection or positive cui-
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Table 2. CMV Disease: Manifestations and Sites 
Regimen 
Acyclovir + 
Acyclovir Alone Globulin 
Clinical manifestations Number of Number of 
Patients (%) Patients (%) 
Viral syndrome 1 (5) 2 (12) 
Localized disease 15 (75) 15 (88) 
Disseminated disease 4 (20) 0(0) 
Sites of invasive CMV 
Gastric/duodenal 14 (70) 15 (88) 
mucosa 
Urine 2 (12) 
Bronchi/lungs 5 (25) 
Retina 1 (5) 
ture. without symptoms. Symptomatic CMV disease (SCD) was 
classified as viral syndrome. localized CMV disease. or dissemi-
nated CMV disease.' Viral syndrome was considered as the 
association of laboratory documentation of CMV infection and 
fever> 38°C for 2 or more days with either atypical lymphocytosis 
> 3%. white cell count <4000/mm.3 or platelet count < 100.0001 
mm:' Localized CMV disease was defined as the invasion of a 
single organ determined histopathologically andlor by culture of 
virus from tissue. Disseminated CMV was considered to be a tissue 
involvement of two or more noncontiguous sites. 
Disease severity was based on six features defined previously 
by Simmons;" (1) prolonged fever (temperature >38.3°C for 
more than 7 days); (2) diffuse pulmonary infiltrate: (3) gastro-
intestinal bleeding; (4) pancreatitis; (5) transplant nephrectomy; 
(6) development of another systemic infection. Patients with 
severe CMV disease had at least three of these six features; 
patients with moderate disease had two of these features; mild 
disease was defined by the presence of not more than one of 
these features. 
Proportions were analyzed using chi-square or Fisher's Exact 
Test when appropriate. A significant difference was defined as 
p < .05. 
RESULTS 
The overall rates of ACI and SCD were 5% and 32%. 
respectively. The incidence of SCD differed significantly 
between group I (47%) and group 2 (23%) (P = . III ). The 
median day for SCD diagnosis was () 7 days (range, 25 to 178 
days) in group I and 87 days (range, 14 to 365 days) in 
group 2. The rate of ACI did not differ significantly between 
group 1 (1%) and group 2 (7%) (P = .41). 
In both groups. localized CMV disease was the most 
frequent clinical manifestation (Table 2) and was most 
frequently documented in the gastrointestinal tract. How-
ever. CMV pneumonia was observed only in group I. 
In group I. moderate to severe disease was observed in 
7s ci- of the patients. including two lethal cases. In group 2. 
the degree of the disease was always mild: no deaths were 
attributable to CMV. 
The overall rate of rejection episodes was higher in group 
I (56%) than in group 2 (34%) (P = .(38). There was also 
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a difference in administration of OKT3 to treat steroid-
resistant acute cellular rejection (ACR). In group 1,8 of 43 
patients (19%) received OKT3: 3 of 73 patients (4%) were 
given OKT3 in group 2 (P = .025). However. rejection did 
not seem to affect the development of CMV in either group; 
in group 1. 10 of 24 patients (42%) previously treated for 
rejection developed SCD vs 10 of 19 patients (52%) never 
treated for rejection (P = .5); in group 2, SCD was 
diagnosed in 8 of 25 patients (32%) treated for rejection 
and in 9 of 48 patients (19%) never treated 
(P = .3). 
Overall one-year patient and graft survival rates were 
93% and 70% in group 1, and 93% and 87% in group 2. 
No difference was observed in the incidence of SCD in 
group 1 for the patients receiving CyA (10 of 23 patients, 
43%), compared with the patients receiving FK 506 (10 of 
20 patients. 50%; P = .9)_ 
DISCUSSION 
The availability of gancyclovir to treat CMV has been a 
critically important development in transplantation. It has 
transformed CMV from a feared. potentially lethal disease, 
into a largely manageable problem. Preventing CMV, how-
ever, is still preferable because it reduces morbidity and 
cost. The prophylaxis literature thus far looked at single 
agents, high-dose acyclovir.5 CMV hyperimmuneglobulin;~ 
and gancyclovir.b Although there are reports suggesting 
that these single agents can be effective. there are also 
disappointing studies. It seems logical to try a combination 
of agents to optimize prophylaxis and reduce the rate of 
CMV in the high-risk group as much as possible. The 
combination of high-dose ACV and CMV -Ig is the first step 
in this direction. In our experience. this combination was 
more effective than high-dose ACV alone. reducing the rate 
of CMV disease in this series from 47% to 23%. In 
addition. the severity of illness seemed to be attenuated in 
the combination therapy group. 
At the present time. we are conducting a prospective. 
randomized trial comparing the combination of high-dose 
ACV and CMV-Ig with a 2-week course of prophylactic 
gancyclovir followed by high-dose ACV. Other potential 
options might include using all three agents. ie. gancyclovir, 
CMV-Ig, and high-dose ACV. In addition. monoclonal 
antibodies to CMV are being evaluated. Further investiga-
tion will be required to establish the best prophylactic 
regimen for CMV: this study suggests that the combination 
of high-dose ACV and CMV-Ig may be useful. 
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